Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
flywheel
.
D E S C R I P T I O N
This invention relates to a process for the prepare-
lion of basically substituted acetonitriles.
It is known that basically substituted phenol asset-
nitrites have coronary vasodilator and anti arrhythmia
properties and are therefore valuable medicaments for
the treatment of various coronary diseases. The best
known substance is a-isopropyl-a-[(N-methyl-N-homoveratryl)-
~-aminopropyl]-3 ? 4-dimethoxyphenylacetonitrile (verapamil,
DEEPS 1 154 aye).
Various processes for the preparation of such basically
substituted phenylacetonitriles have been disclosed in
DEEPS 1 154 810, DEEPS 1 158 083~ DEMOS 2 059 923, DROPS
119 579 and DEMOS 3 121 766.
In the process described in DEEPS 1 15~ 810, the
best known compound of this class of substances? verapamil,
is prepared from ~-isopropylveratryl cyanide corresponding
to the formula
ON
3 / C-H
OH 3
SHEA 3
The starting material for this compound is 3,4-dimethoxy-
bouncily cyanide. according to OrganiXum, VEX Dicier
Verlagder Wissenschaften, Berlin 1976, pages 412 and 270,
and DROPS 9451, this compound is prepared from veratrol
and formaldehyde/aqueous Hal and reaction of the sheller-
methyl compound with Nan. When the process described
in the literature for the preparation of 3,4-dimethoxy-
fly
bouncily cyanide was repeated ? in no case could the yields indicated in the literature be obtained. Only small
quantities of 3,4-dimethoxy-benzyl chloride were obtained,
which did not enable a-isopropyl-veratryl cyanide to
be prepared economically.
Moreover, these processes are not applicable on a
technical scale since it is difficult to prepare the
intermediate product corresponding to the formula:
SHEA ON
SHEA } C-(CH2)3-halogen
/ ! \
SHEA H SHEA
with sufficient purity and in high yields.
In DEMOS 2 263 527 there is described a process for
the preparation of ~erapamil in which ~-isopropyl-veratryl
cyanide is reacted with 3-methyl-formamido-1-chloropropane
to form 2-(3,4-dimethoxyphenyl)-2-isopropyl-5-methyl-
formamidovaleronitrile, which is condensed with homoveratrylaldehyde after the formic acid group has been split off.
This process also provides only low yields.
In DE-AS 2 631 222 there is described a process for
the preparation of basically substituted finalist-
nitrites in which an ~-isopropyl-benzyl cyanide is condensed
with an w-halogen acutely and the nitrite acutely obtained
is then converted into the nitrite alluded by reaction
with aqueous acid, and the nitrite alluded is then sub-
jetted to a hydrogenating condensation with an amine.
In all these processes the preparation of the
starting materials from which they are obtained involves
difficulties so that the desired end product is only
obtained in low yields.
It is an object of the present invention to provide
a new and simplified process for the preparation of
verapamil and related compounds.
This object is achieved according to the invention
~235~3~)
by a process for the preparation of basically substituted
phenylacetonitriles corresponding to the general formula
R'\ ON R5 R1
R C_CH2-CH2-CH2-N SHEA SHEA R2 (I)
wherein R', R'', R''', R , R and R denote, independently
of one another, a hydrogen atom, a halogen atom, a lower
alkyd group, a lower alkoxy group, a lower alkylmercapto
group or an amino group which is optionally moo- or
disubstituted by a lower alkyd group; R4 denotes a straight
chained or branched aliphatic hydrocarbon group having
1 to 6 carbon atoms or a saturated or unsaturated cyclic
hydrocarbon group having 5 or 6 carbon atoms and R5 denotes
a hydrogen atom or a lower alkyd group ? characterized
in that a compound corresponding to the general formula
II
R'' C-Hal (II)
R''' R4
wherein R', R'', R''' and R have the meanings indicated
akove-and Hal stands for a halogen atom, is reacted with
a cyanide of the formula Mohican, wherein Me denotes a
monovalent metal, to form the nitrite of formula III
I H
R'' CON (III)
R''' R4
wherein R', R'', R''' and R4 have the meanings indicated
above and the resulting compound III is reacted with
a substituted propionitrile corresponding to the general
formula IV
2 2 (IV)
12359L3~)
wherein Y denotes a lower alkoxy group or the group NH~Z
wherein Z represents a lower alkyd group a C5-C6-cyclo-
alkyd group or an optionally substituted phenol group?
and the resulting compound V
I ON
C-CH2-CH2-CN (V)
R'''
wherein R', R'', R''' and R4 have the meanings indicated
above is reduced in the presence of a phenylethylamine
corresponding to formula VI
R5 R1
H~N-CH2-~H2- 3R2 (VI)
wherein R1, R2, R3 and R5 have the meanings indicated
above, and the substance obtained is optionally converted
into a pharmacologically acceptable salt by reaction
with a physiologically acceptable acid.
In the general formula It R', R''? R''' 7 R ? R and
R3 represent, independently-of one another a hydrogen
atom? a halogen atom such as a fluorine chlorine, bromide
or iodine atom, a lower alkoxy group such as a buttocks,
n- or i-propoxy, ethics or methoxy group? a lower alkyd
Marquette group such as an ethyl- or methyl-mercapto group,
I or an amino group which may be moo- or disubstituted
by a lower alkyd group. The term "lower alkyd group"
is used here to denote an alkyd group having 1 to 4 carbon
atoms. By "lower alkoxy group" is meant an alkoxy group
having 1 to carbon atoms in the alkyd moiety. R4 denotes
a straight chained or branched aliphatic hydrocarbon
group having 1 to carbon atoms preferably a lower
alkyd group ? in particular a methyl group or a saturated
or unsaturated cyclic hydrocarbon having 5 or 6 carbon
~Z35~3~
atoms ? ton example a cyclopentyl or cyclohexyl group
or a cyclopentenyl or cyclohexenyl group. R5 denotes
a hydrogen atom or a lower alkyd group such as a n- or
i-butyl~ n- or i-propyl, ethyl or methyl group, the latter
being preferred. In the formula Mohican denoting a metal
cyanide used in the first stage, Me stands for a monovalent
metal, for example potassium or sodium, the latter being
preferred. In formula IV, Y stands for a lower alkoxy
group as defined above or the group NH-Z wherein Z denotes
a lower alkyd group, a C5-C6-cycloalkyl group or a sub-
stituted or unsubstituted phenol group. The substituents
optionally used on the phenol group may be, for example
halogen atoms or lower alkyd groups.
In the first stage of the process according to the
invention, the compound corresponding to formula II is
reacted with the metal cyanide. Compound II may easily
be prepared from the corresponding alcohol and the cores-
pounding aqueous hydraulic acid. The reaction is carried
out at 10 to 40C and preferably using aqueous hydrochloric
acid. Thus, for example, a-isopropyl-veratryl alcohol
corresponding to the formula
Ho H SHEA
SHEA \ f-C
l 0 ¦ H SHEA
/\/
SHEA
may be reacted with aqueous hydrochloric acid to form
the corresponding compound II. Compound II is reacted
with a metal cyanide, preferably sodium cyanide, in the
presence of a phase transfer catalyst such as the Seattle
trimethylammonium salt or tetrabutylammonium salt and
1 to 10% by weight of water to form the nitrite correspond-
in to formula III. The reaction is preferably carried
out in an alkaline medium, preferably in a amine such
as triethylamine? and at a temperature of 30 to 80C.
As already mentioned, the reaction is carried out in
the presence of a phase transfer catalyst. The reaction
isle
under conditions of phase transfer is carried out by
the general methods described in Synthesis 1973, pages
441 and 447.
In the next stage of the process according to the
invention, compound III obtained in the first stage is
reacted with a p-substituted propionitrile corresponding
to the general formula IV. The reaction is carried out
in an inert solvent such as dimethylformamide and at
a temperature of from 40 to 90C. By this method, compound
V may be obtained pure in a virtually quantitative yield.
In the third stage of the process according to the
invention, the dinitrile compound of formula V is reduced
in the presence of a phenol ethyl amine compound of formula
VI. This reduction is preferably carried out as a catalytic
hydrogenation using a noble metal catalyst, preferably
Pd/C. In a preferred procedure for carrying out this
stage? the dinitrile V is reacted with 0.9 to 1.5 equiva-
fonts? preferably 1.0 to 1.1 equivalents of the phenol
ethyl amine compound of formula VI or a salt thereof and
to 10~ by weight based on the amine, ox the Pd/C
catalyst which contains 1 to 10% by weight of Pod, based
on the quantity of C 7 and the reaction is carried out
at temperatures from 30 to 80C? preferably at 60C,
at normal pressure or under an excess pressure of up
to 6 bar. The solvents used may be lower alcohols ? acetic
acid or aromatic hydrocarbons, preferably lower aliphatic
alcohols such as ethanol. The reaction mixtures are worked
up by conventional methods.
The resulting compound of formula I may? if required,
be converted into a pharmacologically acceptable salt
thereof.
Both inorganic and organic acids are suitable. Examples
of inorganic acids include hydrochloric acid and hydra-
bromic acid. Oxalic acid is an example of a suitable
organic acid. Any pharmacologically suitable inorganic
or organic acids could in principle be used for conversion
into a physiologically acceptable salt.
~Z359~1 30
Compared with the known processes of the state of
the art, the process according to the invention provides
the advantages of a smaller number of stages, better
partial and total yields and the use of milder and physic-
logically less harmful reagents,
The invention is illustrated by the Examples,
~35~3~
E x a m p 1 e
a Preparation ox a-isopropylveratrYl cyanide
457.4 g (2 molt of -isopropyl-veratryl chloride?
10~ g (2.2 molt of sodium cyanide ? 1 0 mow-% of phase
transfer catalyst, 100 ml ox water and 800 ml of in-
ethyl amine are stirred together for 5 hours at 60C.
After the addition of 60 ml of 30% sodium hydroxide
solution and 300 ml of water? the organic phase is
separated off. After removal of the triethylamine
by distillation? the residue is distilled in a fine
vacuum. The distillate obtained is recrystallized
from methanol/water.
Yield: 310 g - 71% of the theoretical, melting range:
50 to 52C.
b) Preparation of 4-(3,4-dimethoxyphenyl)-4-cyano-5-
methylcapronitrile
438.4 g (2 molt of -isopropyl-veratryl cyanide and
204.2 g ~2.4 molt of 3-methoxypropionitrile are dissolved
in 400 ml of dimethylformamide? 36 ml of a 5.5 molar
solution of sodium methyl ate are added, and the mixture
is heated to 85C for 1/2 hour. After cooling, water
is added to the reaction mixture and the reaction
product separates by crystallization. Recrystallized
from methanol/water, the product melts at 97C.
Yield: 506 g - 92.9~ of theoretical.
c) Propriety on of -isopropyl-a-[(N-methyl-N-homoveratrYl)-
aminopropyl]-3,4-dimethoxyphenylacetonitrile
40~ g (1.5 molt of 4-(3,4-dimethoxyphenyl)-4-cyano-5-
methylcapronitrile and 30 g of Pd/C~ 5%, are suspended
in 1700 ml of isopropanol in a hydrogenation apparatus
and the whole apparatus is flushed with nitrogen.
After the addition of 20 ml of Decrypt A I, a stream
of hydrogen is passed through the apparatus with vim-
porous stirring and the receiver is filled with hydrogen.
325 g (1.66 molt of N-methyl-homoveratrylamine are
added to the reaction mixture, which is then hydrogen-
... .. . .
if Z3S~3(;~
o
axed at 50 to 60C under a light excess hydrogen
pressure. Hydrogenation is completed after 4 to 6
hours.
After removal of the catalyst ? the isopropanol solution
is concentrated by evaporation under vacuum. The residue
is taken up in ethyl acetate. Isopropanolic Hal is
added to the solution until the reaction is acid.
The verapamil-HCl which crystallizes out is suction
filtered and recrystallized from isopropanol.
White crystals, melting range: 139.7 to 145C.
E x a m p l e 2
Preparation of ~-isopropyl-a-[(N-homoveratryl)-aminopropyl]-
3,4-dimethoxyphenylacetonitrile
272 g (1.0 molt of 4-(3,4-dimethoxyphenyl)-4-cyano-5-
methylcapronitrile and 15 g of Pd/C, 5%, are suspended
in 1100 ml of isopropanol in a hydrogenation apparatus
and the whole apparatus is flushed with nitrogen. 20 ml
of Decrypt A are added and a stream of hydrogen is
passed through the apparatus with vigorous stirring and
the receiver is filled with hydrogen. After the addition
of 200 g (1.1 molt of homoveratrylamine, hydrogenation
is carried out under a light excess hydrogen pressure
for 4 to 5 hours at 50 to 60C.
After removal ox the catalyst ? the isopropanol solution
is concentrated by evaporation under vacuum The oily
residue is taken up in 600 ml of ethylene chloride and
the solution is washed once with 600 ml of ON Hal, then
with 300 ml of water, and the solvent is drawn off under
vacuum. The residue is dissolved in 800 ml of ethyl acetate
in the heat. Norverapamil-HCl which crystallizes out
is suction filtered and recrystallized from isopropanol.
White crystals, melting point: 141.1 to 142.1C,
yield: 339 g 71%
YO-YO
